Barclays Initiates Coverage of Life Science Tools and Diagnostics Firms | GenomeWeb

NEW YORK (GenomeWeb) – Investment bank Barclays on Tuesday initiated coverage of the life science tools and diagnostics industry with the start of coverage on five firms and the upgrade of another company in the molecular diagnostics and omics tools space.

In a report, analyst Jack Meehan initiated coverage of Thermo Fisher Scientific and Myriad Genetics with Overweight ratings. He also gave Equal Weight ratings to Illumina and Agilent Technologies, and an Underweight rating to Hologic, while he upgraded Qiagen to an Overweight rating.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The Wall Street Journal speaks with patients affected by questionable test results from Theranos.

Researchers link variants in TACR3 to hot flashes during menopause, Live Science reports.

Kuwait says it will alter its law requiring citizens and visitors to provide DNA samples, New Scientist reports.

In Science this week: convergent evolution in bird hemoglobin, and more.